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The aim of the study was to evaluate the relationship between several lung function indices and perceived 
dyspnoea during bronchoconstriction. Acute changes in lung function were induced by inhaled histamine 
followed by terbutaline, in 12 asthmatics and 12 subjects with chronic obstructive pulmonary disease (COPD). 
A bipolar visual analogue scale (VAS), allowing subjects to report either improvement or worsening when 
moving off from a ‘nochange’ midpoint, was used to rate shortness of breath. Large swings in ratings were 
seen in all asthmatics and in seven out of 12 COPD subjects (high perceivers). Using linear regression of VAS 
rating against parallel change in lung function, on a within-subject basis, the highest degree of correlation 
between dyspnoea and objective response was found to involve the change in specific inspiratory resistance 
(sRin) in the asthmatics. In the five low perceivers, the ability to discriminate an increase in airway 
obstruction, estimated as the VAS/change in lung function slope, was very poor. Using a stepwise multiple 
regression analysis, the sensation of dyspnoea was found to be significantly related to the FEV, and the sRin 
in the asthmatics, to the inspiratory vital capacity and the maximal inspiratory flow at 50% FVC (MIF,,) in 
the COPD subjects with high perception, and to the MIF,, in the COPD subjects with low perception. 
Introduction 
Since the initial report, by Rubinfeld and Pain in 
1976 (l), that some subjects with asthma are unable 
to perceive marked bronchoconstriction, there have 
been relatively few studies to investigate this fur- 
ther. The group of Killian using a Borg scale, has 
quantitated the sensation of dyspnoea during hista- 
mine challenge in the lung function laboratory, and 
reported a linear relationship between the subjective 
response and the fall in FEV, in two studies involv- 
ing large numbers of asthmatics (2,3). In two 
studies also performed in the lung function labora- 
tory, Turcotte et al. have emphasized that dyspnoea 
perception during the early response to either hista- 
mine, antigen exposure or exercise does not differ 
appreciably (4), but that it is reduced during the 
late asthmatic response, because of temporal adap- 
tation to slowly progressive bronchoconstriction (5). 
The perception of airway obstruction by asthmatics 
in everyday life, with its spontaneous within-day 
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and between-day variability, has been studied by 
Peiffer et al. (6); these authors assessed perception 
as the strength of the correlation between dyspnoea 
and peak expiratory flow (PEF) recorded at home 
and confirmed the early suggestion by Rubinfeld 
and Pain that some asthmatics are ‘poor perceivers’. 
A common feature of all these studies involving 
asthmatics is that only forced expiratory indices 
were analysed. 
In the present study, large variations in airway 
obstruction were induced in two groups of patients 
having asthma or chronic obstructive pulmonary 
disease (COPD) using inhaled histamine followed by 
terbutaline. Shortness of breath was rated on a 
bipolar visual analogue scale (VAS) validated previ- 
ously (7), and lung function measurements included 
forced expiration and inspiration manoeuvres pre- 
ceded by assessment of the specific airway resistance 
during tidal breathing. Previous studies performed in 
a setting of bronchodilation have suggested that 
inspiratory indices, as they are free from any collapse 
artefact, may be more relevant (8) and more closely 
related to dyspnoea (7,9,10) than are the convention- 
ally used FEV, and PEF. This study attempted to 
assess the contribution of several lung function indi- 
ces to the sensation of perceived dyspnoea during 
histamine-induced bronchoconstriction. 
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Patients and Methods 
PATIENTS 
Twenty-four outpatients attending the Chest Clinic 
agreed to participate in a study of respiratory sensa- 
tions at rest. Conditions for entry into the study were: 
(1) physician-diagnosed asthma or COPD; (2) airway 
obstruction (FEV, <850/o predicted and a FEVJIVC 
ratio ~65%); (3) baseline FEV, >50% predicted, and 
(4) no past history of respiratory failure. Lung func- 
tion testing, including a bronchodilation test with 
2OOpg salbutamol delivered by a metered dose 
inhaler, had been performed in all subjects at least 
three times (at least l-week interval) over a time span 
of at least 3 months. Subjects were classified as 
having either asthma or COPD using the criteria 
described previously (7). 
Briefly, asthmatics were never smokers, had a 
history of episodic breathlessness and wheeze and 
had shown an increase in FEV, exceeding 15% 
predicted (11) at least once following 200 pug salbuta- 
mol. COPD subjects were smokers or ex-smokers, 
had a history of chronic cough, sputum production 
and dyspnoea on exertion and had shown no increase 
in FEV, exceeding 10% predicted. Twelve subjects 
(eight males, four females) were considered as having 
asthma, 12 (all men) as having COPD. Mean ( l SEM) 
age, height and weight were 60 ( * 4) years, 170 ( f 2) 
cm, 76.5 ( f 3.1) kg in the asthma group, and 66 
( f 3), years, 169 ( f 2) cm, 69.2 ( f 4.5) kg in the 
COPD group, respectively. COPD patients were pre- 
dominantly ex-smokers (10 out of 12). In the asthma 
group, 10 out of 12 subjects were on maintenance 
drug therapy including inhaled steroids (n= lo), 
inhaled sympathomimetics (n = 8) oral theophylline 
(n=5), inhaled anti-cholinergics (n=2), and oral 
steroids (n= 1). In the COPD group, six subjects had 
no regular therapy while six subjects were on either 
inhaled sympathomimetics (n = 3) inhaled anti- 
cholinergics (n=3) or oral theophylline (n=2). 
STUDY DESIGN 
All the subjects gave informed consent and the 
study protocol was approved by the Ethics Commit- 
tee of the Hopital Universitaire Brugmann, Belgium. 
The study consisted of consecutive inhalations of 
histamine with assessment of subjective perception 
and of lung function, and was single blind, with the 
supervisor knowing which agent was inhaled while 
the subject did not. All the subjects were naive to 
sensory evaluation. The protocol included l-5 in- 
halations of histamine, depending on the degree of 
bronchial reactivity (see below) followed by two 
inhalations of terbutaline. All subjects were asked to 
abstain from inhaled bronchodilators after 7 am, 
with the sessions starting at 3 pm. Oral theophylline 
preparations were withheld 48 h before testing. Oral 
and inhaled steroids were not withheld. After arrival 
in the lung function laboratory, each subject rested 
comfortably on a chair for 10 min and a full expla- 
nation of the method used to evaluate dyspnoea 
perception was given. Baseline lung function was 
subsequently measured. The patient was then given 
the first inhalation and thereafter rested in the sitting 
position. After a 2-min interval, the subject was 
invited to rate the change in shortness of breath and 
lung function was measured again. The subse- 
quent inhalations were given and the procedure 
of subjective response rating and lung function 
measurement was repeated at each step. Due to the 
potential severity of bronchoconstriction induced, a 
physician with resuscitation equipment was present 
at all times. 
DOSAGE OF INHALED AGENTS 
A Mefar MB3 dosimeter (Medicali, Brescia, Italy) 
activated by the subject’s inspiratory manoeuvre was 
used (12). The method of inhalation was the same as 
that used in previous studies and is fully described 
elsewhere (7). Different histamine concentrations 
were used in asthmatics and in COPD subjects, as 
shown in Table 1. Histamine doses so obtained were 
in agreement with usual recommendations, including 
a first dose of 1Opg or less in subjects with asthma 
(13) and a dose range up to about 1OOOpg in COPD 
subjects (14,15). The diluent of histamine solutions 
was phosphate buffered saline. In all subjects, the 
histamine challenge was stopped when either FEV, 
had fallen below 60% of its baseline value or the 
specific inspiratory resistance (sRin) had increased 
above 250% of its baseline value (or above 
25 cm H,O s in subjects having a baseline value 
5 10). All subjects were subsequently given two 
inhalations of the commercially available 
10 mg ml ~ ’ terbutaline solution (cumulated terbu- 
taline doses 400 and SOOpg). The dose of histamine 
responsible for a fall of 15% in predicted FEV, 
(PD,5p FEV,) was calculated in each subject by 
linear interpolation. 
VISUAL ANALOGUE SCALE 
At the beginning of the session, the patient was 
given a standardized neutral information, fully 
described in a previous study (7). Dyspnoea percep- 
tion was measured using a bipolar VAS (7,16) pre- 
senting as a 40 cm horizontal line, with a ‘nochange’ 
midpoint and ‘much shorter of breath’ (left end) and 
‘much less short of breath’ (right end) descriptors. 
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Table I Concentration and dose of inhaled histamine used in subjects with either asthma or 
COPD 
Concentration Dose Cumulated dose 
(mgml-‘) @s) @s) 
Asthma COPD Asthma COPD Asthma COPD 
Step 1 0.125 0,500 5 20 5 20 
Step 2 0.125 0,500 5 20 10 40 
Step 3 0.250 1 10 40 20 80 
Step 4 0.500 4 20 160 40 240 
Step 5 2 16 80 640 120 880 
This scale allows subjects to report either improve- 
ment or worsening when moving off from the 
nochange midpoint. All ratings were reported as % of 
line length (range - lo&+ 100%). It was carefully 
recommended to the subjects that they rate only 
shortness of breath, and ignore other sensations such 
as cough, chest tightness, nasal irritation or throat 
irritation. 
LUNG FUNCTION 
The methods used for lung function measurement 
are fully described elsewhere (7). Briefly, plethysmog- 
raphy aimed to measure sRin during tidal breathing 
and FRC. The inspiratory vital capacity (NC) was 
measured during a smooth and slow inspiratory 
manoeuvre, from RV up to TLC. Finally, expiratory 
and inspiratory flow-volume curves were obtained. 
Indices retained for analysis are sRin (cm H,O s) 
FRC, IVC, FEV, (1 or % predicted) (17) and maxi- 
mal inspiratory flow at 50% FVC (MIF,,) (1 s - ‘). 
While two or three technically acceptable curves were 
obtained for the baseline evaluation as well as after 
the terbutaline inhalations, only one curve was 
obtained after histamine inhalation, to minimize 
deep inspiration-induced bronchodilation, as recom- 
mended by Scott and Kiing (18). Repeat forced 
manoeuvre was only performed when the first was 
technically unsatisfactory or affected by a poor 
subject effort. 
STATISTICAL ANALYSIS 
Lung function variables were reported as mean 
(& SEM) values. The relationship of the subjective 
perception assessed with the VAS (reference point: 
beginning of the session) to the changes in lung 
function [AsRin (cm H,O s), AFRC, AIVC, AFEV, 
(“XI predicted) AMIFSO (1 s - ‘)I was first studied using 
linear regression analysis on a within-subject basis. 
The number of points included in the regression 
analysis ranged between four and seven. For each 
index, the strength of the correlation was assessed by 
the Pearson correlation coefficient. The slope (resolu- 
tion of the scale) and the VAS axis intercept (percep- 
tion level when no change has occurred in lung 
function) were calculated for the VASlAFEV, and 
VASlAsRin analyses. These correlation coefficients, 
slopes and intercepts were reported as median values 
(with ranges). Secondly, a stepwise multiple regres- 
sion of VAS ratings was performed within each 
group of patients, with the parallel changes in lung 
function as independent variables. The ratings con- 
sidered for this analysis were those obtained after the 
first and last histamine inhalation and after the two 
subsequent terbutaline inhalations. The criteria used 
in the stepwise regression were 0.05 for the probabil- 
ity of ‘F-to-enter’ and 0.10 for the probability of 
‘F-to-remove’. 
Results 
BASELINE SPIROMETRY AND HISTAMINE 
REACTIVITY LEVEL 
The baseline FEV, (mean f SEM) was similar in 
asthmatics: 1.87 ( f 0.15) 1 or 68.7 ( f 2.4) % pre- 
dicted, and in COPD subjects: 1.75 ( f 0.12) 1 or 62.5 
( f 1.9) % predicted. Histamine challenge included 
two inhalations in five asthmatics and four COPD 
subjects, three inhalations in three asthmatics and 
two COPD subjects, four inhalations in two asthmat- 
ics and two COPD subjects. Six subjects (two with 
asthma and four with COPD) were given a fifth 
inhalation. In the asthma group, sRin (all subjects) 
and/or FEV, (three of 12 subjects) threshold for 
stopping the challenge was reached in all the subjects. 
In the COPD group, the threshold was reached in 
nine subjects (sRin alone in four, sRin and FEV, in 
five). One subject was unresponsive to histamine (end 
provocation values: sRin 9.7 cm H,O s, FEV, 96% of 
baseline). The test was stopped in one subject as he 
felt markedly short of breath (VAS - 60%) before 
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Fig I Perceived change in shortness of breath, rated on the bipolar visual analogue scale (VAS), in 12 patients with 
asthma (a), seven COPD patients with high perception (b) and five COPD patients with low perception (c). VAS ratings arc 
expressed as % of line length (range - lOO-+lOO%). The two white arrows represent respectively the first and the last 
histamine inhalation, while the two black arrows represent the two terbutaline inhalations. 
sRin (202% baseline) and FEV, (69.5% baseline) had 
reached their thresholds and in another subject 
with low baseline sRin (3.6) when it attained 
22.5 cm H,O s. The median PD,,,FEV, was 18.8pg 
(range 54-120.0) in the asthma group and 49,Opg 
(range 17.9467.7) in the COPD group. Log 
PD,,,FEV, and baseline FEV, were correlated in the 
COPD group (r=0.664, PcO.05) but not in the 
asthmatics (r=0.064). 
PATTERN AND LEVEL OF PERCEPTION 
Individual dyspnoea ratings are shown in Fig. 1. 
A majority of subjects (17 of 24) rated either no 
change or an improvement in dyspnoea after the 
first histamine inhalation. At the end of the provo- 
cation, all subjects but two felt shorter of breath 
than at the beginning of the session. In the asthmat- 
ics, AVAS, defined as the difference between the 
highest and the lowest rating obtained at any time 
of the study, ranged between 35-102.5% (median 
60%). As shown in Fig. 2, a bimodal distribution of 
AVAS was observed in the COPD group, with 
seven subjects using a large proportion of the scale 
(AVAS 45-100%, median SO%), like the asthmatics, 
while the five other subjects had a low level of 
perception (AVAS 5-35%, median 20%). These two 
subgroups of COPD patients are further designated 
as ‘high perceivers’ and ‘low perceivers’. Dyspnoea 
decreased in all subjects following terbutaline, with 
only a small change in VAS rating in the COPD 
Asthma 
1:: /---l-J 
2 
% 
2 COPD 
i’! 
O-19 20-39 40-59 66-79 80-99 lo&119 
AVAS(%) 
Fig. 2 Histogram of change in visual analogue scale rating 
(dVAS), defined as the difference between the highest and 
the lowest rating for dyspnoea obtained at any time of the 
study, expressed as % of line length. The distribution is 
bimodal in the COPD group. 
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Table 2 Lung function variables 
Asthma 
(n= 12) 
COPD COPD 
high perceivers low perceivers 
(n=7) (n= 5) 
sRin 
(cm H,O s) 
FRC 
0) 
IVC 
(1) 
FE!‘, 
(1) 
MIF,, 
(I s- ‘) 
Baseline 
Post-histamine 
Post-terbutaline 
Baseline 
Post-histamine 
Post-terbutaline 
Baseline 
Post-histamine 
Post-terbutaline 
Baseline 
Post-histamine 
Post-terbutaline 
Baseline 
Post-histamine 
Post-terbutaline 
10.5 ( f 0.9) 11.1 (hO.8) 8.7 ( f 2.3) 
36.5 ( f 2.6) 28.7 ( i 1.0) 30.2 ( zt 55) 
9.9 (i 1.4) 9.8 (f 1.1) 6.7 ( f 0.7) 
4.61 ( f 0.33) 4.89 ( f 0.36) 5.16 (+ 0.25) 
5.83 ( LIZ 0.38) 5.62 ( f 0.42) 6.24 ( f 0.97) 
4.68 ( f 0.35) 4.90 ( f 0.30) 5.25 ( f 0.41) 
3.53 ( f 0.25) 3.50 ( f 0.22) 3.76 ( f 0.27) 
2.27 ( f 0.25) 2.52 ( f 0.16) 2.68 ( f 0.37) 
3.56 ( f 0.26) 3.56 ( f 0.29) 3.71 ( f 0.45) 
1.87 ( f 0.15) 1.72 ( f 0.12) 1.80 ( f 0.17) 
1.18 (kO.13) 1.19 (hO.12) 1.17 ( f 0.31) 
1.92 ( f 0.14) 1.69 ( f 0.14) 1.74 ( f 0.15) 
3.2 (kO.3) 3.5 ( f 0.3) 3.0 ( f 0.5) 
1.7 ( f 0.3) 2.3 ( f 0.4) 2.1 (+0.4) 
3.1 (*0.3) 3.5 ( f 0.2) 3.0 ( f 0.5) 
Mean ( + SEM) values. sRin, specific inspiratory resistance; MIF,,, maximal inspiratory flow at 
50% FVC. 
low perceivers (Fig. 1). Hence, an alternative defini- 
tion for low perception could be a terbutaline- 
induced increase in VAS rating (VAS after 800,~g 
terbutaline minus VAS after last histamine inhala- 
tion) less than 25%. The latter definition, which was 
successfully used in two previous studies dealing 
with perception of a 8OOpg terbutaline dose (7,10), 
would lead to the same discrimination between 
seven high perceivers and five low perceivers within 
the COPD group, and would classify all asthmatics 
as high perceivers. Within the COPD group, there 
was no significant difference between high and low 
perceivers in either age, proportion of regular users 
of inhaled bronchodilators or bronchial reactivity 
level. 
SIZE OF CHANGE IN LUNG FUNCTION 
Lung function variables are reported in Table 2 
at baseline, after maximal bronchoconstriction and 
after subsequent bronchodilation. There was little 
difference between asthmatics, COPD high perceivers 
and COPD low perceivers in either baseline, 
post-histamine or post-terbutaline values. 
RELATIONSHIP OF VAS RATING TO OBJECTIVE RESPONSE: 
WITHIN-SUBJECT ANALYSIS 
The analysis of within-subject correlations between 
VAS rating and change in lung function is summa- 
rized in Table 3. The closest correlations were 
observed in the asthma group, and the highest 
median r value corresponded with the relationship 
between VAS and AsRin (rx0.953). To evaluate 
whether stronger correlations between subjective and 
objective response were encouraged or not by larger 
variations in lung function, the correlation between r 
values (reflecting the strength of the VAS/change 
in lung function relationship) and size of the 
corresponding change in lung function in the whole 
group of 24 subjects was studied, and no significant 
relationship was found. 
Individual examples of linear regression analyses 
are shown in Fig. 3. From the latter figure, it 
appears that a relatively high r value in the COPD 
low perceivers is of limited significance, as all VAS 
ratings were close to zero, and, as a consequence, 
the slope of the regression line close to zero, too. 
Table 4 shows the perceptual characteristics of the 
three groups of patients, the most striking point 
again being the very poor resolution of the scale 
in the COPD low perceivers. Table 4 also shows 
that median VAS axis intercepts were around 
+20% in the two groups of subjects with high 
perception. 
RELATIONSHIP OF VAS RATING TO OBJECTIVE RESPONSE: 
MULTIPLE REGRESSION ANALYSIS 
In the asthmatics, the sensation of dyspnoea was 
significantly related to the change in FEV, (P=O.O02) 
and in sRin (P=O.O22). No other independent vari- 
able entered the equation after AFEV, and AsRin 
were introduced. In the COPD high perceivers, the 
significant predictors of the variation in shortness of 
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Table 3 Relationship between VAS rating and parallel change in lung function (within-subject 
analysis) 
Asthma 
(n= 12) 
COPD COPD 
high perceivers low perceivers 
(n=7) (n=5) 
sRin 0.953 (0.670-0.993) 0.704 (0.359-0.995) 0.797 (0.084-0.968) 
FRC 0.890 (0.055-0.976) 0.518 (0.2360.874) 0.531 (0.105-0.837) 
IVC 0.946 (0.528-0.995) 0.810 (0.2240.989) 0.533 (0.077-0.940) 
FEV, 0.934 (0.423-0.998) 0.693 (0.3594.956) 0.745 (0.03220.920) 
MIF,, 0.869 (0.2760980) 0.805 (0.3954.970) 0.532 (0.118-0.887) 
Data in the table are median Pearson correlation coefficients (range) between VAS rating and 
parallel change in lung function. VAS, bipolar visual analogue scale; sRin, specific inspiratory 
resistance; MIF,,, maximal inspiratory flow at 50% FVC. 
(a) 
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F = 0.670 
(b) 
I F = 0.995 
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Fig 3 Individual examples of linear regression of visual analogue scale (VAS) rating against the change in specific 
inspiratory resistance (sRin): subjects with the best (top) and the worst (bottom) r values from each group; (a) asthma; 
(b) COPD high perceivers; (c) COPD low perceivers. Numbers refer to the order of the successive inhalations. 
breath were the change in IVC (P=O.OlO) and in COPD, high perceivers VAS= 
MIF,, (P=O.O12); while in the COPD low perceivers, 17.2+ 1.36 AIVC + 19.18 AMIF,, r=0.800 
only the change in MIF,, (P=O.O03) entered the COPD, low perceivers VAS= 
equation. 3.4+28.94 AMIF,, rz0.630 
The regression equations are: 
(VAS % of line length, AFEV,, AIVC% predicted, 
Asthmatics VAS = AsRin cm H,O s, AMIF,, 1 s - ‘, r multiple coefficient 
15.1+1.19 AFEV, -0.83 AsRin rz0.811 of correlation) 
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Table 4 Characteristics of the perception of acute changes in lung function 
COPD COPD 
Asthma high perceivers low perceivers 
(n= 12) (n=7) (n=5) 
Slope +2.1 (+1.0-+3.1) +3.5 (+ 1.5-+4.2) +0.6 (CL+ 1.5) 
FEV, 
VAS axis intercept + 19 (- 14-+45) +22 (- 9-+56) +I (-l-+16) 
Slope -2.4 (-0.9--2.9) -2.6 (-1.9--3.2) -0.4 (+0.2--2.6) 
sRin 
VAS axis intercept +20 ( - 28-+48) +16 (- 26+30) +l (-2-+15) 
Values are expressed as median (range). Slopes are expressed as % of VAS line length per % 
predicted of change in FEV, (or per cm H,O s of change in sRin), intercepts as % of VAS line 
length. VAS, bipolar visual analogue scale; sRin, specific inspiratory resistance. 
Discussion 
In the present study, large variations in airway 
obstruction, using histamine, and subsequently terb- 
utaline, were induced in 24 subjects with impaired 
baseline lung function and a diagnosis of either 
asthma or COPD, and the subjective response was 
measured as a change in dyspnoea on a bipolar VAS. 
The swings in VAS ratings were small in five COPD 
subjects, defined as low perceivers on the basis of a 
post-800pg terbutaline increase in VAS ~25% of line 
length. The strongest individual correlation between 
VAS rating and lung function involved the change in 
sRin in the asthmatics. As judged from a stepwise 
multiple regression analysis, the significant contribu- 
tors to the sensation of dyspnoea were FEV, and 
sRin in the asthmatics, and IVC and MIF,, (MIF,, 
alone in the low perceivers) in the COPD subjects. 
In previous studies dealing with the perceived 
dyspnoea during bronchoconstriction, only FEV, 
was considered. On a study of 45 asthmatics, Burdon 
et al. (2) reported a linear relationship between 
histamine-induced dyspnoea and the fall in FEV,, 
with, however, a large between-subject variability in 
subjective response for a given decrease in FEV r . In a 
more recent study including 120 asthmatics, the same 
group confirmed that dyspnoea intensifies signifi- 
cantly, although variably, as FEV, decreases (3). In a 
population study involving 412 subjects with bron- 
chial hyperreactivity, Brand et al. (19) found larger 
decreases in FEV, in those subjects with higher 
increases in Borg ratings; however, in a multiple 
regression analysis the relation of the histamine- 
induced change in FEV, to that in dyspnoea was no 
longer significant after adjustment for such variables 
as age, sex, skin test reactivity, bronchial reactivity 
level and smoking habits. The present study was 
designed to evaluate the correlation between 
dyspnoea and a large set of lung function indices, 
including plethysmographic specific resistance, static 
lung volumes (FRC, IVC) and forced expiratory 
(FEV,) or inspiratory (MIF,,) indices. In the asth- 
matics, a variable degree of individual relationship 
between dyspnoea and change in lung function vari- 
ables was found, with sRin showing the closest 
correlation (median r=0.953, lowest individual 
r 0.670). Similar findings were observed when study- 
ing the perception of progressive, terbutaline- 
induced, bronchodilation in a similar group of 
asthmatics (lo), and the strong relationship between 
dyspnoea and sRin was ascribed to the fact that the 
latter variable better reflects bronchodilation than 
e.g. forced expiratory indices, which are influenced by 
changes in large airways collapsibility (20) or in lung 
elastic recoil (21). In the present study, an additional 
factor could be the stretch receptors-mediated 
decrease in bronchial tone induced by deep inspira- 
tion in some subjects with pharmacologically- 
induced bronchoconstriction (22). Every effort was 
made to minimize the latter phenomenon by asking 
the subjects to slowly inspire to TLC before the 
forced expiratory manoeuvre (23), and by recording a 
single flow-volume curve after each histamine inha- 
lation (18). However, despite this careful design, deep 
inspiration-induced bronchodilation did occur in 
some individuals and in those subjects, the indices 
measured on the forced respiratory manoeuvres 
underestimated the degree of obstruction present at 
the time the patient had rated dyspnoea on the scale. 
This study included subjects with COPD as well as 
asthmatics. We are not aware of data in the literature 
about the perception of bronchoconstriction by 
COPD subjects. Some COPD patients were found to 
perceive acute changes in lung function poorly. That 
some subjects perceive dyspnoea at a low level, and 
with poor relation to the objective response, has been 
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a constant finding in previous studies dealing with the 
perception of bronchodilation in similar groups of 
COPD outpatients, selected on basis of clinical his- 
tory and limited reversibility in airway obstruction 
(7,lO). Perception of added resistive loads has been 
shown to be impaired in COPD subjects, but not in 
asthmatics (24), and this impairment has been 
ascribed to a defect in the central nervous system 
processing of sensory information (25). In the present 
study, it was not possible to definitely identify any 
factor associated with high or low perception within 
the COPD group. It may be hypothesized that the 
muscular breathing pattern -which was not evalu- 
ated in this study - was possibly different, although 
voluntary use of either the diaphragm or the inter- 
costal muscles by healthy subjects submitted to a 
resistive load has been found to produce similar 
intensities of dyspnoea (26). An alternative hypoth- 
esis could be that high and low perception reflect 
different levels of awareness to sensory stimuli, 
associated with distinct psychologic profiles (27). In 
a stepwise multiple regression analysis of dyspnoea 
against lung function, the change in IVC and MIF,, 
were found to be significant contributors to the 
variation in shortness of breath in the COPD group 
with high perception. This result compares well with 
previous reports by Bellamy and Hutchison (9) and 
by our group (7,lO) that the ability of COPD subjects 
to perceive an acute bronchodilation as a decrease 
in dyspnoea is linked to some improvement in 
inspiratory function. 
In the present study, the VASlobjective response 
relationship was found to have a positive intercept in 
most subjects. The median VAS axis intercept, 
reflecting the subjective rating for no change in 
FEV,, amounted to + 19%, in the asthma group, and 
+22% in the COPD subjects with high perception. 
These results show that a given threshold of bron- 
choconstriction has to be reached before being per- 
ceived as an increase in shortness of breath. Further 
studies are needed to evaluate the relevance of this 
finding in a setting of spontaneous bronchoconstric- 
tion. Kikuchi et al. studied 11 asthmatics with a 
history of near fatal asthma and reported in these 
subjects an increased threshold for dyspnoea when 
breathing through inspiratory resistances, in com- 
parison with a control group of 11 asthmatics with- 
out history of near fatal asthma (28). If we admit that 
over-tolerance to dyspnoea may lead to failure to 
appreciate life-threatening asthma, educational inter- 
ventions aimed to improve awareness of bronchoc- 
onstriction are desirable in those subjects with poor 
perception. Preliminary data suggest that perception 
of airway obstruction can be trained (29) and that 
regular recording of PEF at home could be a useful 
intervention (30). 
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